A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1408 participants.
Also called NCT07919405
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,408 participants
- Sponsor
- Registry
-
NCT07919405
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Denmark, Germany, Hungary, Italy, Japan, Netherlands, Poland, Puerto Rico, South Africa, South Korea, Spain, United Kingdom
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07919405. Randomized; quadruple masking; primary purpose treatment. Start 2026-11-11 (anticipated); primary completion 2028-06-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity
- Acronym
- REDEFINE
- Condition
- Hypertension
- Condition
- Obesity
- Intervention (Drug)
- CagriSema
- Intervention (Drug)
- Semaglutide
- Intervention (Drug)
- Cagrilintide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct07919405- Content hash
ac7d67baf47a9c11c377eb0a6bfad2a29bc20b84f28160e2eab672046b4c1e1e